Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This is a multiple‐center, randomized, double‐blind, placebo‐controlled Phase IIb study to evaluate the efficacy and safety of AK101, an anti‐IL‐12/23 p40 antibody, when administered subcutaneously, in subjects with moderate‐to‐severe plaque psoriasis. The study will consist of 3 periods: up to 4 weeks screening, 12 weeks double‐blinded treatment and long‐term follow‐up period(up to 52 weeks).
Epistemonikos ID: ce1954f5a76dc804e558cfa8c1f642cfe4ea3cca
First added on: May 06, 2024